MK-3475-992 / KEYNOTE-992试验：Pembrolizumab（MK-3475）在化学放疗联合化疗和仅化疗治疗肌层侵袭性膀胱癌中的疗效和安全性。
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy Versus Chemoradiotherapy Alone in Muscle-invasive Bladder Cancer: The MK-3475-992/KEYNOTE-992 Trial.
发表日期：2023 Feb 01
作者：
Gabrielle Tissot, Evanguelos Xylinas
来源：
European Urology Focus
摘要：
最大限度切除膀胱肿瘤后联合放疗和敏化化疗的三模式治疗是对肌层侵袭性膀胱癌的替代治疗选择。对于特定病例，这种方法在回顾性分析中表现出可比性，与新辅助化疗后进行根治性膀胱切除的结果相似。为了改善尿道保留策略的肿瘤学结果，当前三模式设计加入了围手术期免疫疗法作为第四种治疗模式。版权所有 © 2022。Elsevier B.V.出版。
Trimodal therapy comprising maximal transurethral resection of bladder tumor followed by radiation therapy with sensitizing chemotherapy is an alternative treatment option for muscle-invasive bladder cancer. This approach has shown comparable results to those with neoadjuvant chemotherapy followed by radical cystectomy in retrospective analyses for selected patients. Efforts to improve oncological outcomes of bladder-preserving strategies have converged on adding perioperative immunotherapy as a fourth treatment modality to the current trimodal design.Copyright © 2022. Published by Elsevier B.V.